Mechanisms of atrial-selective block of Na + channels by ranolazine: I. experimental analysis of the use-dependent block

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Zygmunt, Andrew C ^a   Nesterenko, Vladislav V ^a   Rajamani, Sridharan ^b   Hu, Dan ^a   Barajas Martinez, Hector ^a   Belardinelli, Luiz ^b   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmia; Ion channels; Pharmacology

Indexed keywords

RANOLAZINE; SODIUM CHANNEL NAV1.5; SODIUM ION;

ANIMAL EXPERIMENT; ARTICLE; DEPOLARIZATION; DIASTOLE; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; FEMALE; HEART ATRIUM; HEART MUSCLE CELL; HEART VENTRICLE; HUMAN; HUMAN CELL; MALE; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PULSE RATE; SODIUM CURRENT; VOLTAGE CLAMP;

ACETANILIDES; ALGORITHMS; ANIMALS; BINDING SITES; DATA INTERPRETATION, STATISTICAL; DOGS; FEMALE; HEART RATE; HEK293 CELLS; HUMANS; KINETICS; LINEAR MODELS; MALE; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERAZINES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 80053226953     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00242.2011     Document Type: Article

References (32)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas GP. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation 110: 904-910, 2004.
2. Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol 42: 543-548, 2009.
3. Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol 81: 613-642, 1983.
4. Burashnikov A, Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol 14: 290-300, 2009.
5. Burashnikov A, Di Diego JM, Sicouri S, Ferreiro M, Carlsson L, Antzelevitch C. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm 5: 1735-1742, 2008.
6. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116: 1449-1457, 2007.
7. Carmeliet E, Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol 70: 1-72, 1998.
8. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 292: H66-H75, 2007.
9. Draper NR, Smith H. Applied Regression Analysis. New York: Wiley- Interscience, 1998.
10. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148: 16-24, 2006.
11. Gilliam FR, Starmer CF, Grant AO. Blockade of rabbit atrial sodium channels by lidocaine. Characterization of continuous and frequencydependent blocking. Circ Res 65: 723-739, 1989.
12. Grant AO, Dietz MA, Gilliam FR 3rd, Starmer CF. Blockade of cardiac sodium channels by lidocaine. Single-channel analysis. Circ Res 65: 1247-1262, 1989.
13. Hondeghem LM, Katzung BG. Mechanism of action of antiarrhythmic drugs. In: Physiology and Pathophysiology of the Heart, edited by Sperelakis N. Dordrecht, The Netherlands: Kluwer Academic, 1995, p. 589-603.
14. Kaliebe JW, Murdock DK. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report. WMJ 108: 373-375, 2009.
15. Maier SK, Westenbroek RE, McCormick KA, Curtis R, Scheuer T, Catterall WA. Distinct subcellular localization of different sodium channel a and b subunits in single ventricular myocytes from mouse heart. Circulation 109: 1421-1427, 2004.
16. Makielski JC, Satin J, Fan Z. Post-repolarization block of cardiac sodium channels by saxitoxin. Biophys J 65: 790-798, 1993.
17. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S, Severski P, Rosero S, Daubert JP, Qi M, Cieciorka M, Manalan AS. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 10: 59-66, 2005.
18. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19: 1289-1293, 2008.
19. Murdock DK, Kersten M, Kaliebe J, Larrian G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a reveiw of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 9: 260-267, 2009.
20. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 8: 175-181, 2008.
21. Murdock DK, Reiffel JA, Kaliebe J, Larrian G. The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for a new "pill-in-pocket" approach in structural heart disease. J Atr Fibrillation 2: 705-710, 2010.
22. + channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol. First published August 5, 2001; doi:10.1152/ajpheart.00243.2011.
23. - current by ranolazine. Heart Rhythm 6: 1625-1631, 2009.
24. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non STElevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116: 1647-1652, 2007.
25. Starmer CF. Characterizing activity-dependent processes with a piecewise exponential model. Biometrics 44: 549-559, 1988.
26. Starmer CF, Lastra AA, Nesterenko VV, Grant AO. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 84: 1364-1377, 1991.
27. Starmer CF, Nesterenko VV, Undrovinas AI, Grant AO, Rosenshtraukh LV. Lidocaine blockade of continuously and transiently accessible sites in cardiac sodium channels. J Mol Cell Cardiol 23, Suppl I: 73-83, 1991.
28. Starmer CF, Nesterenko VV, Undrovinas AI, Packer DL, Gilliam FR, Grant AO, Rosenshtraukh LV, Strauss HC. Characterizing ion channel blockade with the guarded receptor hypothesis. In: Molecular and Cellular Mechanisms of Antiarrhythmic Agents, edited by Hondeghem LM. Mount Kisco, NY: Futura Publishing, 1989, p. 179-200.
29. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17: S161-S177, 2006.
30. + channel isoforms by ranolazine. Mol Pharmacol 73: 940-948, 2008.
31. Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol 6: 153-158, 2001.
32. Zygmunt AC. Intracellular calcium activates chloride current in canine ventricular myocytes. Am J Physiol Heart Circ Physiol 267: H1984-H1995, 1994.